SAT0110 SARCOPENIA IN PATIENTS WITH RHEUMATOID ARTHRITIS ON THE TREATMENT WITH BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS. (2nd June 2020)

• Record Type: Journal Article
• Authors: Hasegawa, E.; Ito, S.; Kurosawa, Y.; Taniguchi, S.; Kobayashi, D.; Abe, A.; Otani, H.; Nakazono, K.; Murasawa, A.; Narita, I.; Ishikawa, H.
• Is Part Of: Annals of the rheumatic diseases. Volume 79(2020)Supplement 1
• Page Start: 989
• Page End: 989
• Publication Date: 2020-06-02
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2020-eular.1036
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Sarcopenia is characterized by loss of muscle mass and strength, which lead to lower physical ability, less quality of life (QoL), frailty and mortality. Rheumatoid arthritis (RA) is considered to be one of the causes of sarcopenia. Objectives: To clarify the effectiveness of biologic disease modifying anti-rheumatic drugs (bDMARDs) on sarcopenia, including physical ability, body composition and nutritional status. Methods: This is a prospective cohort study including consecutive 48 patients (male 11, female 37, age 64.2±15.1) with RA who started bDMARDs in Niigata Rheumatic Center. Diagnosis of sarcopenia was according to the diagnostic algorithm of European Working Group on Sarcopenia in Older People (EWGSOP). We monitored disease activity of RA, physical ability, body composition, nutritional status and QoL at baseline, 6 months and at 12 months. Disease activity was measured by disease activity score-28 joint count based on erythrocyte sedimentation rate (DAS28-ESR), clinical disease activity index (CDAI). Physical activity was measured by Health Assessment Questionnaire (HAQ), 10m walking test (10MWT). Nutritional status was measured by controlling nutrition status (CONUT) score, and prognostic nutritional index (PNI). Overall QoL was measured by EuroQol 5 dimentions (EQ5D). Results: Among 48 patients who started bDMARDs, 21 patients were classified as having sarcopenia. The bDMARDs used were adalimumab in 10 cases, certolizumab pegol in 9 cases, abatacept in 9 cases, golimumab in 7 cases, tocilizumab in 5 cases, infliximab in 5 cases and etanercept in 3 cases. DAS28-ESR (4.7±1.4 vs. 2.7±1.0, p < 0.001) and CDAI (18.4±9.4 vs. 7.4±5.5, p<0.001) were significantly decreased by 12 months of bDMARDs therapy. Physical activity was significantly ameliorated after 12 months of bDMARDs; HAQ(1.1±0.9 vs. 0.6±0.8, p<0.001), 10MWT(1.5±0.7 m/s vs. 1.7±0.6, p=0.002). EQ-5D was also ameliorated(0.63±0.15 vs. 0.74±0.19, p=0.0002). As for body composition analysis, there were significant increase in body weight(54.6±12.4 kg vs. 55.8±13.6, p=0.006), but there was no significant increase in skeletal muscle mass index(5.9±1.1 kg/m2 vs. 5.9±1.1, p=0.229). Among 21 patients who were classified as sarcopenia when starting bDMARDs, the number of patients having sarcopenia significantly decreased after 12 months of bDMARDs (100% vs. 52.3%, p=0.0005) and skeletal muscle index of these patients were significantly increased (5.1±0.5 kg/m2 vs. 5.3±0.7, p=0.046). Conclusion: Twelve months of bDMARDs therapy significantly ameliorated disease activity, nutritional status and physical activity. In RA patients with sarcopenia, bDMARDs significantly increased skeletal muscle and may be effective for treatment of sacrcopenia. Disclosure of Interests: Eriko Hasegawa: None declared, Satoshi Ito Speakers bureau: Abbvie, Eisai, Yoichi Kurosawa: None declared, Shinji Taniguchi: None declared, Daisuke Kobayashi: None declared, Asami Abe: None declared, Hiroshi Otani: None declared, Kiyoshi Nakazono: None declared, Akira Murasawa: None declared, Ichiei Narita: None declared, Hajime Ishikawa: None declared